The estimated Net Worth of William A. Waldegrave is at least $346 Thousand dollars as of 10 July 2019. William Waldegrave owns over 3,576 units of GW Pharmaceuticals stock worth over $250 and over the last 6 years he sold GWPH stock worth over $0. In addition, he makes $345,769 as Non-Executive Independent Director at GW Pharmaceuticals.
Sign up
William Waldegrave GWPH stock SEC Form 4 insiders trading
William has made over 1 trades of the GW Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 3,576 units of GWPH stock worth $250 on 10 July 2019.
The largest trade he's ever made was exercising 3,576 units of GW Pharmaceuticals stock on 10 July 2019 worth over $250. On average, William trades about 715 units every 0 days since 2019. As of 10 July 2019 he still owns at least 3,576 units of GW Pharmaceuticals stock.
You can see the complete history of William Waldegrave stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Waldegrave biography
The Rt. Hon. Lord William Arthur Waldegrave serves as Non-Executive Independent Director of the Company. Lord Waldegrave served as a Conservative Member of the British Parliament from 1979 to 1997 including 16 years as a Government Minister, of which seven years were as a Cabinet Minister (Minister of Agriculture, Chief Secretary of the Treasury, Secretary of State for Health, and Chancellor of the Duchy of Lancaster with responsibility for the Civil Service Reform and Science). Educated at Oxford University and Harvard (a Kennedy Scholar), before entering Parliament he worked in the Cabinet Office in Whitehall; as Political Secretary to Prime Minister Edward Heath; and for GEC Ltd. Lord Waldegrave is currently Provost of Eton College, Chancellor of Reading University and a Distinguished Fellow of All Souls College, Oxford and an Honorary Fellow of Corpus Christi College, Oxford. From 1998-2008 he worked at Deutsche Kleinwort Benson and UBS. From 1998–2016, he was a director (1998-2012) and then Chairman (2012-2016) of Biotechnology Growth Trust plc. Lord Waldegrave was appointed Chairman of Coutts in January 2014 and is Chairman of the Royal Mint Advisory Committee, former Chairman of the Rhodes Trust, a Founder Trustee of the Mandela Rhodes Foundation (South Africa), and a former Chairman of the National Museum of Science and Industry. Lord Waldegrave also holds an honorary Doctorate of Civil Law from the University of Reading.
What is the salary of William Waldegrave?
As the Non-Executive Independent Director of GW Pharmaceuticals, the total compensation of William Waldegrave at GW Pharmaceuticals is $345,769. There are 11 executives at GW Pharmaceuticals getting paid more, with Justin Gover having the highest compensation of $7,864,300.
How old is William Waldegrave?
William Waldegrave is 73, he's been the Non-Executive Independent Director of GW Pharmaceuticals since 2017. There are no older and 13 younger executives at GW Pharmaceuticals.
What's William Waldegrave's mailing address?
William's mailing address filed with the SEC is SOVEREIGN HOUSE, VISION PARK, HISTON, , CAMBRIDGE, X0, CB24 9BZ.
Insiders trading at GW Pharmaceuticals
Over the last 6 years, insiders at GW Pharmaceuticals have traded over $60,899,192 worth of GW Pharmaceuticals stock and bought 7,200 units worth $48,960 . The most active insiders traders include Geoffrey W Dr Guy, James Noble, and Justin D. Gover. On average, GW Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $8,011. The most recent stock trade was executed by Douglas B. Snyder on 6 April 2021, trading 8,400 units of GWPH stock currently worth $152,208.
What does GW Pharmaceuticals's logo look like?
Complete history of William Waldegrave stock trades at GW Pharmaceuticals
GW Pharmaceuticals executives and stock owners
GW Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Justin Gover,
Chief Executive Officer, Executive Director -
Geoffrey Guy,
Executive Chairman of the Board -
Volker Knappertz,
Chief Medical Officer -
Douglas Snyder,
Chief Legal Officer -
Scott Giacobello,
Chief Financial Officer -
Christopher Tovey,
Chief Operating Officer -
Adam George,
Managing Director - U.K., Company Secretary -
Cabot Brown,
Non-Executive Independent Director -
James Noble,
Non-Executive Independent Director -
Catherine Mackey,
Non-Executive Independent Director -
Alicia Secor,
Non-Executive Independent Director -
William Waldegrave,
Non-Executive Independent Director -
David Gryska,
Independent Director -
Stephen Schultz,
Vice President, Investor Relations -
Darren Cline,
Chief Commercial Officer - U.S. -
Thomas G Lynch,
Director -
Julian S Gangolli,
President, North America